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Abstract  
 
One of the most important factors, affecting the pharmacokinetic profile of a drug is 
binding to plasma protein. As such, this study aimed at the development of a quantitative 
structure–activity relationship model, to predict the fraction unbound in plasma (fub) for four 
species, using artificial neural network ensemble (ANNE). 
To this end a database of 363 drugs was used, and molecular descriptors were 
determined. The dataset was divided in two groups, a train and an external validation, to 
avoid overfitting. The ANNE optimization reduced the descriptors required to determine the 
fub to 37, and 150 ANN were randomly selected, trained and the optimal configuration was 
collected. The different ANNE were built by averaging the output values of the selected 
ANN and the best ANNE was selected.  
The model created was able to predict, with a small amount of error, the fub values 
(root mean square error of 0.16798 and 0.193705 for train and test dataset respectively), 
however, it tends to underestimate this value (mean error of -0.00291 and -0.015780 for train 
and test dataset respectively). The ANNE interpretation showed that the main characteristics 
of that affect fub
 were the molecule charge, size, structure and lipophilic and hydrophilic 
affinity. 
Key-words: ANNE, ANN, plasma protein binding, QSAR, fraction unbound in plasma 
 
Resumo 
 
Um dos factores mais influentes na farmacocinética de um fármaco é a ligação às proteínas 
plasmáticas. Sendo assim, com este estudo pretendeu-se desenvolver um modelo QSAR, para 
prever facção do fármaco livre no plasma (fub) para quatro espécies, usando um “ensamble” 
de redes neuronais (ANNE). 
Para tal, utilizou-se uma base-de-dados de 363 fármacos, e determinou-se os seus descritores 
moleculares. Esta base-de-dados foi dividida em dois grupos, um para treino e outro para 
validação externa, para evitar “overfitting”. O ANNE foi optimizado, reduzindo o número de 
descritores para 37, e 150 redes foram aleatoriamente selecionadas, treinadas e a sua 
configuração optimizada registada. Os diversos ANNE foram obtido através da média 
aritmética dos valores das redes seleccionadas, e o melhor ANNE foi escolhido.  
Este modelo foi capaz de prever com um erro reduzido, o valor da fub (erro quadrático médio 
de 0.16798 e 0.193705 para o grupo de treino e teste respectivamente), no entanto 
tendencialmente subestima o seu valor (erro médio de -0.00291 e -0.015780 para o grupo de 
treino e teste respectivamente). A interpretação do modelo permitiu observar que o tamanho 
da molécula, a sua estrutura, carga, lipofilia e hidrofilia são as características que mais 
afectam o valor da fub. 
Palavras-chave: ANNE, redes neuronais, ligação a proteínas plasmáticas, QSAR, fração 
livre no plasma 
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Pharmacokinetics and Drug Fraction Unbound in Plasma 
 
Pharmacokinetics is the science that provides a mathematical basis to assess the time 
course of drugs in the body, as such it incorporates the processes of absorption, distribution, 
metabolism and excretion (ADME) [1] [2] [3]. 
The effectiveness of a drug dosage is determined by the concentration of the drug in 
the body, and ideally, it should be measured at the site of action of the drug. To understand 
the importance of the drug substance and its formulation on absorption, and distribution of 
the drug to the site of action, one must first consider the sequence of events that precede its 
therapeutic effect, as described in Figure 1 [1] [2]. 
 
Figure 1 - Scheme demonstrating the dynamic relationship between the drug, the drug product, and the 
pharmacologic effect [2] 
As consequence, a fundamental understanding of these parameters is required to 
design an appropriate drug regimen for a patient, or even to design a new drug for testing, as 
almost 39% of the costly late-stage failures in drug development until the late 1990s were 
caused by poor pharmacokinetics, and even in recent years, about 15% of failures in drug 
development are due to this reason [1] [2] [4] [5]. 
However, since measuring the concentration of a drug in its site of action is difficult, 
concentrations are normally measured in whole blood from which serum or plasma is 
generated. The simplest pharmacokinetic concept is that based on total drug in plasma, 
however, drug molecules may be bound to a greater or lesser extent to the proteins present 
within the plasma, thus free drug levels may be vastly different from those of total drug 
levels.  Additionally, only the unbound fraction of the drug can produce the desired 
pharmacological effect and be metabolized [1] [3]. 
Plasma protein binding (PPB) of drugs is expressed as percentage of total drug that 
is bound to plasma protein such as albumin, α1-acid glycoprotein (AAG) and lipoproteins. A 
number of acidic drugs have high affinity for sites on blood proteins, particularly albumin, 
whereas the main binding protein for many basic drugs is AAG. Each protein have its own 
proprieties, their concentration in plasma may vary depending on gender, age and health state 
and they can contribute simultaneously to the binding of the drug [6] [7] [8] [9].  
PPB is a reversible association of a drug with the proteins of the plasma due to 
hydrophobic and electrostatic interactions such as van der Waals and hydrogen bonding. The 
unbound drugs can passively diffuse through the barriers into the organs where they are 
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metabolized, biliary excretion or glomerular filtration in kidney, and to the sites where they 
interact with therapeutic targets to produce therapeutic effects [6] [7]. 
Since numbers of protein-binding sites are limited, competition will exist between 
two drugs, and the drug with higher affinity will displace the other, causing increased free 
drug. The protein-binding properties are related to plasma clearance, elimination half-life, 
apparent volume of distribution and area under curve [10].  
 
QSAR for Fraction Unbound in Plasma 
 
As consequence of what was written in the previous chapter, the analysis of the PPB 
drug capability is a vital attribute for the assessment of the drug’s pharmacokinetics and 
pharmacological effects and also the toxicity risk that the drug may pose [6] [7] [11]. 
There are several in vitro assays that can be used to determine the extent of plasma 
protein binding, such as equilibrium dialysis, ultrafiltration, ultracentrifugation, 
chromatographic methods, fluorescence spectroscopy, ultraviolet spectroscopy, circular 
dichroism, nuclear magnetic resonance spectroscopy, and capillary electrophoresis [6] [12] 
[13]. 
However in vitro and in vivo ADME are relatively expensive in terms of resources, 
reagents and detection techniques, therefor there is a need for reliable in silico technique to 
predict PPB of virtual compounds in order to avoid the synthesis of chemicals which do not 
have the potentiality of being approved drugs, and also to gain insights into the chemical 
nature of drug–protein interactions [6] [4] [9]. 
One possible approach is the quantitative structure-activity relationship models 
(QSAR), which are computer-based models for the prediction of toxicological, biological and 
physico-chemical properties. They aim at establishing, if it exists, a mathematical relationship 
between structural-derived properties of chemicals and their experimental properties, such as 
toxicity [14] [15] [16]. 
Since a QSAR model is a methodology that starts with generated descriptors based 
on molecular structures and uses computational algorithms to relate the key descriptors to the 
dependent property value of interest, a number of QSAR studies on the analysis and 
prediction of PPB have been performed during the last two decades. Several molecular 
descriptors were used, such as constitutional, topological, electrotopological, 
physicochemical, quantum chemical descriptors and a variety of mathematical models were 
also used, such as multiple linear regression with variable selection, artificial neural networks 
(ANN) and support vector machines (SVM) [4] [9]. 
Nevertheless, prediction of binding affinity of drugs to plasma proteins is a rather 
complicated task, since the quality of the model depends on the quality of the dataset, which 
in this case can be a tricky task because like other pharmacokinetic parameters, binding 
affinity data vary significantly from report to report as a result of differences in methodology, 
experimental conditions, and mathematical approaches [4]. 
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ANN for Developing a QSAR 
 
Applying machine learning algorithms to QSAR models has long been done, it 
started with the used linear regression models, but these were quickly supplanted by Bayesian 
neural networks. The use of ANN for QSAR models appeared in the 90s, and has developed 
into a well- established scientific area with numerous ideas, theoretical approaches, and 
successful practical applications [17] [18] [19]. 
ANN are powerful non-linear models for classification, regression, or 
dimensionality reduction, which maps input vectors to output vectors with repeated 
compositions of simpler modules called layers. The internal layers re-represent the input and 
learn features of the input useful for the task [17] [20]. 
Deep neural networks, or neural networks with multiple hidden layers, have recently 
been highly successful in numerous applications because they are capable of learning 
complicated, rapidly-varying non-linear functions and are also capable of extracting a 
hierarchy of useful features from their input [17] 
Non-Bayesian ANN have also been applied to QSAR, initially with a single small 
hidden layer, but more recently,  a tremendous improvements in training methods for deep 
and wide neural networks as well as a renewed appreciation for the advantages of deeper 
networks as been done [17]. 
In practice, ANNs are used for solving so-called ill-posed problems, for which 
numerous alternative solutions can be suggested. These problem exactly correspond to tasks 
performed by NN in an absolute majority of QSAR studies, by the means of learning or 
training, which can be supervised, unsupervised, or reinforced [18]. 
The advantages of ANN over statistical estimation technique is that no a prior 
knowledge of underlying statistical nature of problem is required and no simplifying 
assumption need to be made for application of this technique in a sparse data environment 
[21].  
However, it is often difficult to decode the final model to identify the changes to 
molecular structure needed to obtain a desired property, and this mathematical model has a 
tendency to ‘memorize’ rather than learn and are particularly susceptible to over-fitting, 
especially if the training data is noisy [20]. 
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Objective 
 
This study aims at the development of a QSAR model to predict plasma protein binding, for 
four different species, human, dog, rat and monkey, using ANN software, and using 
Microsoft Excel to building an ANNE.  
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Materials and Methods 
 
Data Base of Fraction Unbound in Plasma 
 
The QSAR model, was created based on a data set of intravenous pharmacokinetic 
data from human, rat, dog, and monkey for 363 compounds, previously developed by Franco 
Lombardo and his colleges [22]. 
The available fraction unbound in plasma (fub) information was collected for the four 
species. A multifactor ANOVA was preformed to both data sets, using StatPoint Statgraphics 
Centurion v15.2.11., where the two factors analysed were molecule and species. A 
statistically significant difference was observed between the different species, and as 
consequence, a binary input was added to the model to describe each specie (Table 1). 
 
Table 1 - Species binary code 
Human 0 0 
Monkey 0 1 
Rat  1 0 
Dog 1 1 
 
Calculation of the Molecular Descriptors 
 
The following methodology was used for the calculation of the molecular 
descriptors: SMILES notation of each molecule was obtained using the on-line PubChem 
Compound database (http://www.ncbi.nlm.nih.gov), ionization descriptors, i.e. acid pKa and 
base pKa, were predicted by using ChemAxon (http://www.chemicalize.org), additionally, 
for molecules without an acid group a value of 15 was attributed to the acid pKa, and for 
drugs without a basic group, a value of -1 was to  the base pKa. The remaining descriptors, 
related to size, hydrogen bonding potential, lipophilicity and others, were obtained from the 
on-line E-Dragon 1.0 software using CORINA to convert the SMILES notation to the 3D 
representation of the molecule. From all the molecules in the database, twelve were excluded, 
since the E-Dragon Software didn’t accept a molecules with that size (the molecules were to 
big for the software). At the end of the creation of this database, for each one of the 351 
molecules, 1670 descriptors were created. 
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ANNE Optimization 
 
The Artificial Neural Network (ANN) non-linear regression was performed using 
the backpropagation neural modelling system Qnet for Windows v.2000 build 751 (Vesta 
Services inc, USA) and an in-house developed Microsoft Excel® VBA procedures for 
process automation. 
Both molecular descriptors and binary descriptors for species, where considered as 
the ANN input and the fub values where considered as the ANN outputs. It’s important to say 
at this point that, each molecule had an individual input entry for each specie fub values. 
To allow the calculation of the relative relevance of the molecular descriptors, all 
networks designed were built using normalised variables both at the input and output, and a 
sigmoid transfer function was used in all connections. 
In order to avoid network overfitting, input space dimension pruning was preformed, 
and early stopping of training was used, where 25% of the train molecules were randomly 
selected to act as a sub-set for the internal testing of the model, not effectively used in the 
regression process, and ANN train was performed until degradation on the RMSE for the 
internal test data was observed. Furthermore, each network architecture was trained 20 times, 
with random initial values and different sub-sets of the internal test cases, to avoid training 
convergence to local minima. 
The input space dimension pruning was a two-step process. At first, molecular 
descriptors where eliminated based on three factors: 
 Molecular descriptors classification; 
 Molecular descriptors highly correlated (r>0,9); 
 Molecular descriptors with highly repetitive values (90%). 
The second step consisted of the optimisation of the network structure for the most 
relevant molecular descriptors. To this end, ANN with one hidden layer, and a ρ value 
between 2 and 3, where ρ is the ratio between the number of train cases and the number of 
connections in the network, where trained 20 times, and relative input weights and standard 
deviation were collected for all networks. 
The 10 best networks (networks with smallest RMSE) were selected, and the 
molecular descriptors with relative weight smaller than the binary code weights where 
eliminated. This procedures was preformed until no molecular descriptor could be eliminated. 
To reduce the input space further, the same procedure as described above for the 
input weight value was preformed, but this time focused on the standard deviation values. 
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 In the last step of the optimization process, several ANN structures were tested, 
varying the number of hidden layers (up to three) and the number of hidden neurons in order 
to obtain a ρ above 1. To this end, 265 ANN were built, and 150 ANN were randomly 
selected, trained and the optimal ANN configuration for each ANN was collected. 
 After the optimization process, the predicted output values and input weight 
information, for each optimal ANN configuration was collected, and the ANN ensemble 
(ANNE) was built for the best 10, 20, 30, 40, 50, 100 and 150 networks based on the RMSE 
values. 
 
ANN Validation  
 
External validation was done by comparing the values predicted by the best ANNE 
(ANNE with smallest RMSE) to the observed fub values of the drugs in the external 
validation group of data, not previously used in the training and optimization process. 
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Results 
 
Data Base of Fraction Unbound in Plasma 
 
The available fub for the four species were analysed, and a multifactor ANOVA was 
performed using StatPoint Statgraphics Centurion v15.2.11., where the two factors analysed 
were molecule and species. The outcome of this analysis can be seen in Table 2, and as result 
a statistically significant difference was observed between the different species. 
Table 2 - Analysis of Variance for Ligação_1 - Type III Sums of Squares 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
MAIN EFFECTS      
A:Espécie 0.215402 3 0.0718008 2.98 0.0314 
B:Molécula 68.2189 238 0.286634 11.88 0.0000 
RESIDUAL 10.8604 450 0.0241343   
TOTAL (CORRECTED) 79.9453 691    
 
ANNE Optimization 
 
Regarding the reduction of the input space, the subset of E-Dragon 1.0 software 
descriptors chosen for this study are displayed in Table 3. Additional a binary input was 
added to the model to describe each specie. Highly correlated descriptors (r>0.9), and those 
with highly repetitive values (90%) were eliminated, resulting in the reduction of the input 
space from 1670 to 281 descriptors.  
Table 3 - Table of molecular descriptor classes 
Descriptor Class 
Constitutional descriptors 
Topological descriptors 
Walk and path counts 
Connectivity indices 
Information indices 
Topological charge indices 
Geometrical descriptors 
WHIM descriptors 
GETAWAY descriptors 
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Functional group counts 
Molecular properties 
 
The selection of the most relevant descriptors was described under methods, and at 
the end of the first stage, the input space was still too large, since the number of molecular 
descriptors was 197. However, after the second approach, the input space size was reduced to 
37 descriptors, which was considered a reasonable number of molecular descriptors to build 
the ANNE, and can be seen in Table 4. The evolution of the RMSE and correlation of e train 
and test groups during this process of elimination can be seen in Figure 2 and Figure 3. 
 
 
Figure 2 - Evolution of the RMSE with the reduction of molecular descriptor number 
 
Figure 3 - Evolution of the correlation of the predicted and observed values with the reduction of the molecular 
descriptors 
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Table 4 - Molecular descriptors at the end of the ANNE optimization 
Abreviation Description Class 
Bin 1 Species binary code 1 Species 
Bin 2 Species binary code 2 Species 
RBN number of rotatable bonds 
constitutional 
descriptors 
nS number of Sulfur atoms 
nR06 number of 6-membered rings 
J Balaban-like index from topological distance matrix topological 
descriptors D/Dr09 distance/detour ring index of order 9 
SRW05 self-returning walk count of order 5 walk and path 
counts MPC06 molecular path count of order 6 
IVDE mean information content on the vertex degree equality 
connectivity 
indices 
SIC1 Structural Information Content index information indices 
GGI3 topological charge index of order 3 
topological charge 
indices 
JGI4 mean topological charge index of order 4 
JGI5 mean topological charge index of order 5 
JGI6 mean topological charge index of order 6 
DISPe displacement value / weighted by Sanderson electronegativity 
geometrical 
descriptors 
L2u 2nd component size directional WHIM index / unweighted 
WHIM descriptors 
E1v 
1st component accessibility directional WHIM index / weighted by 
van der Waals volume 
E2v 
2st component accessibility directional WHIM index / weighted by 
van der Waals volume 
G2p 
2nd component symmetry directional WHIM index / weighted by 
polarizability 
Du D total accessibility index / unweighted 
H7u H autocorrelation of lag 7 / unweighted 
GETAWAY 
descriptors 
HATS2u leverage-weighted autocorrelation of lag 2 / unweighted 
R3u R autocorrelation of lag 3 / unweighted 
R1u+ R maximal autocorrelation of lag 1 / unweighted 
R6m+ R maximal autocorrelation of lag 6 / weighted by mass 
R5v+ 
R maximal autocorrelation of lag 5 / weighted by van der Waals 
volume 
R5e+ 
R maximal autocorrelation of lag 5 / weighted by Sanderson 
electronegativity 
R5p+ R maximal autocorrelation of lag 5 / weighted by polarizability 
nCs number of total secondary C(sp3) 
Functional group 
count 
nRNH2 number of primary amines (aliphatic) 
nRNR2 number of tertiary amines (aliphatic) 
nOHs number of secondary alcohols 
nArX number of X on aromatic ring 
ALOGPS_logP Gthose-Crippen octanol-water partition coeff. (logP) 
molecular 
properties 
Pka Base Basic pKa 
pKa Acid Acid pKa 
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After the input space was optimized, and in order to optimize the structural space, 
265 ANN were considered, varying the number of hidden layers (up to three) and the number 
of hidden neurons in order to obtain a ρ above 1. Of these, 150 ANN were randomly selected, 
trained and the optimal ANN configuration, based on the lower internal test RMSE for each 
ANN, was collected. 
 
 
Figure 4 - Performance, measured in terms of the train and internal test RMSE, for the 150 ANN during the 
optimization procedure. Complexity of each individual ANN is described by the ratio between the number of 
patterns to the number of connections (r) 
At the end of the ANN optimization an ANNE was built by averaging 10, 20, 30, 40, 
50, 100 and 150 of the best ANN based on the RMSE values for the test group, and the 
predicted output (mean and S.D) for each ensemble was collected. The evolution of the 
RMSE of the mean predicted outputs can be seen in Figure 5, and the comparison of the 
predicted and observed fub for each ensemble can be seen in Figures 6 to 12. 
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Figure 5 - Evolution of the RMSE for each ANNE 
 
Figure 6 - Plot of the observed vs predicted fub in the ensemble with the 10 best ANNs 
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Figure 7 - Plot of the observed vs predicted fub in the ensemble with the 20 best ANNs 
 
Figure 8 - Plot of the observed vs predicted fub in the ensemble with the 30 best ANNs 
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Figure 9 - Plot of the observed vs predicted fub in the ensemble with the 40 best ANNs 
 
 
Figure 10 - Plot of the observed vs predicted fub in the ensemble with the 50 best ANNs 
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Figure 11 - Plot of the observed vs predicted fub in the ensemble with the 100 best ANNs 
 
Figure 12 - Plot of the observed vs predicted fub in the ensemble with the 150 best ANNs 
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The best ANNE was built using the 20 best ANN, i.e. the ANN with smallest 
RMSE, and the statistical evaluation of this ANNE is displayed in Table 5. 
Table 5 - Statistical evaluation of the best ANNE 
APE 0.02822 
RMSE 0.16798 
Mean Error -0.00291 
Max res 0.84147 
Min Res 0.00044 
Spearman correlation 0.85722 
APE – Averaged squared error of prediction 
RMSE – Root mean square error 
Max res – Maximum residue 
Min res – Minimum residue  
Regarding the input weight information, all data was collected, and the average and 
standard deviation was calculated for each input used. Additionally, the average weight of 
each class of molecular descriptors was also calculated.  
Table 6 - Input weight information 
Molecular 
Descriptor 
Average 
Weight 
Standard 
Deviation 
Descriptor 
Class 
Average 
Weight 
Bin 1 0.29 0.138 
Specie 0.69 
Bin 2 0.40 0.091 
RBN 2.37 0.362 
constitutional descriptors 10.94 nS 3.54 0.386 
nR06 5.04 0.345 
J 1.81 0.681 
topological descriptors 3.27 
D/Dr09 1.45 0.325 
SRW05 1.20 0.319 
walk and path counts 4.31 
MPC06 3.11 0.751 
IVDE 2.25 0.501 connectivity indices 2.25 
SIC1 3.98 0.551 information indices 3.98 
GGI3 2.59 0.595 
topological charge indices 10.05 
JGI4 3.35 0.561 
JGI5 1.42 0.515 
JGI6 2.69 0.336 
DISPe 1.74 0.375 geometrical descriptors 1.74 
L2u 2.85 0.561 
WHIM descriptors 16.89 
E1v 2.83 0.389 
E2v 3.45 0.401 
G2p 2.77 0.505 
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Du 4.98 0.374 
H7u 2.29 0.511 
GETAWAY descriptors 21.72 
HATS2u 3.85 0.708 
R3u 3.21 0.539 
R1u+ 3.13 0.504 
R6m+ 2.10 0.534 
R5v+ 2.76 0.540 
R5e+ 2.12 0.448 
R5p+ 2.27 0.715 
nCs 3.69 0.483 
functional group counts 11.48 
nRNH2 2.33 0.423 
nRNR2 1.88 0.302 
nOHs 3.11 0.539 
nArX 0.47 0.261 
ALOGPS_logP 8.50 0.754 
molecular properties 12.67 Pka Base 2.44 0.314 
pKa Acid 1.74 0.403 
 
ANNE Validation 
 
As stated earlier, the external validation was done by comparing the values predicted 
by the best ANNE to the observed fub values of the drugs in the external validation group of 
data, using the best ensemble obtained in the optimization process (ensemble with the 20 best 
ANNs). The statistical information of the ANNE validation is displayed in Table 7 
 
Figure 13 - Plot of the observed vs predicted fub in the ensemble with the 20 best ANNs for the test subset 
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Table 7 - Statistical information for the validation of the best ANNE  
APE 0.037522 
RMSE 0.193705 
Mean Error -0.015780 
Max res 0.781048 
Min Res 0.000048 
Spearman correlation 0.812773 
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Discussion 
 
As stated in the first chapter of this essay, the analysis of the PPB drug capability is 
vital for the assessment of the drug’s pharmacokinetics, pharmacological and toxicological 
effects. Also the PPB capacity of a drug might account for numerous interactions between 
different drugs, because the number of binding sites is limited [6] [7] [10] [11].  
Additionally, the need for reliable in silico technique to predict PPB of existing and 
new drugs is of great importance, in order to reduce development and research cost [6] [4] 
[9].  
To this end, this study aimed at the development of a QSAR model for the prediction 
of drug’s PPB, using an ANNE. Since the binding affinity of drugs to plasma proteins is a 
rather complicated task, because it depends on the quality of the dataset, a previously 
developed dataset of intravenous pharmacokinetic data from human, rat, dog, and monkey for 
approximately 400 compounds was used, since data set was carefully compiled from 
literature reports and expanded with some inhouse determinations for plasma protein, and 
also because to the authors’ knowledge, it was the largest publicly available data set [22]. 
Several QSAR models have already been developed to predict PPB, several types of 
molecular descriptors and size of drug database have been used, however, they provide little 
mechanistic understanding of binding relationships [13] [4].  
Furthermore, no evidence have been found in the bibliographic review of a QSAR 
model that could predict the fub for different species. 
Based on what was stated previously, and given the existence of fub values for 
different species in the database used, it was imperative to evaluate if there was a statistically 
significant difference between de fub of a drug for the different species, because if no 
statistically significant difference was found, the model developed could predict 
automatically the fub for the four species. 
To this end an ANOVA test was performed, and a statistically significant difference 
was observed between the different species for the fub at a 95.0% confidence level.  
This result was expected since previous studies also showed difference in plasma 
protein binding in different species. This fact can be explained by difference in physiology, 
development and biological phenomena in the different species, and also by difference in the 
plasma proteins composition and binding characteristics, due to structural differences 
between species [23] [24] [25] [26] [27].  
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ANNE Optimization and Validation 
 
Optimization of the neural networks was done as reported in methods. Validation is 
a critical aspect of any model construction, for neural network model validation, usually 
model validation is based upon some specified network performance measure of data that 
was not used in model construction (a “test set”) [28] [29].  
The methodology mentioned above is also known as train-and-test and the 
proportion set aside for training of the available data has ranged, in practice, from 25% to 
90%, in this case a 75/25 training testing data set ratio was used [28]. 
Additionally, during the model optimization procedure, and in each individual 
training step, the train data was again divided randomly into an actual train dataset and an 
internal test dataset again in a 75/25 ratio, which is a variation of the train-and-test 
methodology [28].  
This internal train/test random division process was done in order to allow the early-
stop of the optimization, by training until a degradation of the RMSE in the internal 
validation data was observed. This methodology is based on the principal that the test error 
reaches a minimum and then increases as training goes on, while the training error 
monotonically decreases as show in Figure 14 [30]. 
 
 
Figure 14 - Idealized behaviour of training and validation error [30] 
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Nevertheless, in real life, things are a lot more complex with error curves having 
almost always more than one local minimum. The curve showed in Figure 15, which is a 
generic error curve, exhibits as many as 16 local minima and of these local minima, 4 are the 
global minimum up to where they occur [30]. 
 
Figure 15 - Real validation error curve [30] 
 
Due to this fact, each network was run for an excessive number of iterations, and the 
iteration that resulted in the lowest residual mean square error (RMSE) of the testing group 
was kept. Addition, each of the selected ANN structures was started 20 times with random 
initial values, in order to sweep the parameters space and avoid convergence to local minima. 
As can be seen in Figure 4, RMSE of the train datasets, within each individual 
structure, after optimization varied between 0.098 and 0.138, as for the RMSE of the internal 
validation datasets varied between 0.101 and 0.129. 
The similarity of the range of RMSE of training and testing datasets show that the 
early stopping method was able to avoid overtraining and memorization. Additionally, the 
small range of RMSE indicates that local minima was avoided. 
Another problem that could affect the performance of the model, and that had to be 
addressed early in the development process of the ANNE model, was the number of 
molecular descriptors available, because with the increase in size of the ANN system, the 
number of neural connections also increases proportionately. This condition naturally 
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increases the likelihood of training algorithm convergence problems. Besides, the memory 
requirement and the processing time have to be addressed have as well [31].  
To this end the input space dimension reduction was done in a two-step process.  
The first step, was a brute force approach, where molecular descriptors where 
eliminated based on three factors: 
 Only molecular descriptors with the classification mentioned in Table 3 were 
selected; 
 Molecular descriptors highly correlated (r>0.9) were eliminated,  allowing the 
removal of redundant descriptors, which contained information already within another 
descriptor; 
 Molecular descriptors with highly repetitive values (90%) were eliminated, ensuring 
that the neural network wouldn’t fit to a specific kind of molecules, based on the 
training molecules randomly assigned to each network, which would reduce the 
applicability domain of the final model. 
The second step consisted on the optimisation of the network structure for the most 
relevant molecular descriptors, by a pruning process, as described under methods. ANN with 
one hidden layer, and a ρ value between 2 and 3, were used to reduce the ability of the 
network to memorize the data and avoid over-fitting [32]. This ANNs where trained 20 times, 
and relative input weights and standard deviation were collected for all networks. 
The elimination process based on the RMSE and standard deviation values of the 
species binary code, as described under methods, because this attributes were considered a 
priori relevant descriptors, based on the ANOVA test results. 
Additionally, and to validate the input space reduction process, Figure 2 and Figure 
3 show that with the reduction of the number of descriptors, RMSE decreased and correlation  
increased in the test subset, which indicates that this process was able to remove complexity 
to the model, and increased the capability of prediction, without compromising the 
adjustment capability of the model, since the RMSE of the training subset didn’t increase that 
much. 
Furthermore, the results described previously for the correlation parameter, allows 
the conclusion that this reduction process was able to eliminate molecular descriptors that 
only adjusted to small group of molecules. 
Finally, and in order to optimize the ANN architectural  structures, a last step of the 
optimization process consisted on training 150 ANN randomly selected form a set of 256 
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ANN, to ensure a reasonable computational time. The ANN had varying the number of 
hidden layers (up to three) and the number of hidden neurons in order to obtain a ρ above 1, 
because as reported above, it reduces the ability of the network to memorize the data and 
avoids overfitting. 
Subsequently to the optimization process, the ANNE was built for the best 10, 20, 
30, 40, 50, 100 and 150 networks based on the RMSE values, due to the fact that they are 
able to improve generalization performance [33] [34]. 
The creation of an ANNE can be divided into two steps, creating individual 
members, which in these case are the 150 ANN developed, and combining the output of the 
ensemble members, to produce the ensemble output. In this study, this last step was obtained 
by averaging the output data of the ANNs selected for each ensemble [34].   
As can be seen from figure 5 to 12, the best ANNE obtained was the ensemble with 
20 ANN, because it show the best (smallest) RMSE. The results attained here, suggests that 
the evolution of the RMSE isn´t proportional to the number of ANN used in the ensemble, it 
rather shows that the RSME stats to fall with the increasing number of ANN used, however, 
after a while, the RMSE stats to increase and after that this, it tends to maintain a certain level 
of RMSE. 
The results mentioned above, can indicate that although the ANNE provides a better 
generalization performance, if the number of ANN used is too big, the additional ANN added 
are adding noise to the model, instead of creating a better approximation model. 
Analysing the statistical results of the best ANNE for the train dataset, it shows that 
the model has a good ability to adjust to this dataset, since the RMSE is small. Also, it shows 
that the model generally tends to underestimate the values of the fub since the mean error has 
a negative value. 
Additionally for the statistical analysis of the ANNE, a Spearman's rank-order 
correlation was preformed, to measures the strength of association between the fub observed 
and predicted. Given the result (0.85722), there is a good correlation between the values 
predicted and observed [35] [36]. 
Regarding the validation of the ANNE model, the best ANNE was used to obtain the 
predicted output for the test dataset, not previously used in the training and optimization 
process, and the results were compared to the observed values, as showed in Figure 13. 
Analysing the validation results and comparing them to the training results, the 
model has a good ability to predict fub values, since a small RMES was obtained for the 
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previously unused dataset, and this RMSE value although bigger it has the same magnitude 
of the value obtained for the training dataset. Furthermore, and based on the Spearman's rank-
order correlation result, a good correlation between the values predicted and observed can be 
observed. 
 
ANNE Interpretation 
 
As mentioned in methods, to build this model an input size reduction was 
performed. As consequence, and due to the “black-box” nature of the ANN models, it is 
important to create a bridge between the mathematical model, and what occurs in nature. 
To this end, it is not only relevant to analyze the molecular descriptors obtained in 
the optimization process and their relative weights in the final output, but also to understand 
how molecules bind to the plasma proteins, and how this two things relate. 
Frist, let’s start by understanding how drugs interact with plasma proteins, and 
which proteins they interact with. The most important plasma proteins in terms of drug 
binding are albumin and α1-acid glycoprotein, followed by lipoproteins. The serum albumin 
is the primary constituent in human plasma, accounting for 60% of total plasma protein [6]. 
As said earlier, acidic drugs have high affinity to albumin, whereas the main binding 
protein for many basic drugs is AAG. For drugs, there are two main binding sites and a 
variable number of secondary (lower affinity) sites on albumin, both main sites are elongated 
hydrophobic pockets, however, site I especially binds bulky heterocyclic anions (e.g. 
warfarin), whilst site II preferentially recognizes small aromatic carboxylic acids (i.e. 
ibuprofen) [6] [7] [37]. 
Initial studies indicate that binding of drugs to AAG appear to involve hydrophobic 
rather than electrostatic forces, and some acidic drugs such as warfarin can compete with 
basic drugs for what appears to be a single binding site, perhaps in the protein part of the 
glycoprotein molecule [11].  
More recent studies show that both hydrophobic and electrostatic forces have an 
important role in interactions between AAG and drugs. Furthermore, AAG exists in a mixture 
of two or three genetic variants, with different number of binding sites (varying from 2 to 3 
binding sites), and different affinity to drugs and their structural functional groups [38]. 
Lipoproteins, have been described to bind some basic drugs such as chlorpromazine 
and imipramine. The forces involved here are mainly hydrophobic. However the clinical 
relevance of these findings are unclear due to their present in small amounts in blood [4] [11] 
[37]. 
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Regarding the 37 molecular descriptors selected after the ANNE optimization, the 
class with smallest relative weight in the output values is the binary code for the species 
characteristic, since in the optimization process, all molecular descriptors with weight smaller 
to these ones were eliminated.  
After this descriptor class, those with smallest influence in the model are the 
geometrical descriptors, information indices, connectivity indices, topological descriptors and 
walk and path counts. 
The geometrical descriptor selected by the model was the displacement value 
weighted by Sanderson electronegativity, and it represents the displacement between the 
geometric and the electronegativity centres of the molecule [39]. Since the interaction of the 
drugs and the plasma protein depend on the charge of the molecule and it´s 3D structure, it 
makes sense that this descriptor is relevant for the affinity of a drug to a certain protein. 
The connectivity index used by the model is the mean information content on the 
vertex degree equality, which is a measure of the lack of structural homogeneity or the 
diversity of a molecule [40].  
The topological descriptors selected by the model are Balaban-like index from 
topological distance matrix (Balaban distance connectivity index) and the distance/detour 
ring index of order 9. The Balaban distance connectivity index is able to differentiate isomer 
molecules, and as consequence, highlights the importance of the molecular structure in the 
affinity of a drug to the plasma protein, which as stated earlier is a known fact [41]. The 
distance/detour ring index of order 9 is a measure of the cyclicity of the molecule, and as 
such is related to the morphology of the molecule [42]. 
The information indices selected were the Structural Information Content index 
(neighborhood symmetry of 1-order), which is a structure related descriptor, and as stated 
before, the structure of the drug is a major factor for its affinity for the plasma proteins [43]. 
The walk and path counts descriptors selected in the model were the self-returning 
walk count of order 5 and molecular path count of order 6, which also relate to the size, 
complexity and structure of the molecule [44]. 
The descriptor classes with biggest influence in the output values are constitutional 
descriptors, topological charge indices, WHIM descriptors, GETAWAY descriptors, 
functional group counts and molecular properties. 
The constitutional descriptors selected in this model were number of rotatable bonds, 
number of sulphur atoms and number of 6-membered rings, and as their names indicate, they 
represent the flexibility of the molecule, the number of certain kind of atoms or structures in 
the molecule, so they represent structural aspect of the drug. 
The topological charge indices used in the molecule evaluate the charge transfer 
between pair of atoms, and therefor evaluate the capability of the molecule to form dipoles, 
which can be related to the charge affinity of certain molecules to specific binding sites of 
some plasma proteins [45].  
The WHIM descriptors are 3-dimensional molecular indices that represent different 
sources of chemical information such as the whole 3D-molecular structure in terms of size, 
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shape, symmetry and atom distribution, therefore its relevance in the model can be related to 
the structural requirements of the drugs to bind to the plasma proteins [46].  
The GETAWAY descriptors are used to describe the molecular structure of the drug, 
and as such, can be related to the capability of a drug to bind to a plasma protein, the same 
way the WHIM descriptors does [47]. 
 The functional group counts descriptors indicate the number of certain functional 
groups in the molecule, and as such can be related affinity of certain functional groups and 
structural groups to specific binding sites of some plasma proteins.  
The molecular properties define the lipophilic and hydrophilic affinity of the 
molecule, expressed by the logP value, and the ionization state of the molecule, expressed by 
de values of pKa and pKb. Since this properties influence the affinity of the molecules to the 
hydrophilic and lipophilic binding sites of the plasma proteins, and the charge of the 
molecule, it is expected that they contribute heavily to the output value.  
 
Future Research 
 
After this study, it is clear that the model here developed is capable of predicting the 
fub of drugs, with a small amount of error, if molecular descriptors required are calculated. 
Furthermore, the determination of the applicability domain of this model should made, and 
also the different capability of the model to predict the fub for the different species. Additional 
when presenting the final result for a desired molecule, the model should automatically 
correct the value, if a negative value is determined. 
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